+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Nephritogenic Glycoprotein X

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          When triglycosyl glycopeptide (nephritogenoside) was contaminated with glucosyl, galactosyl, mannosyl, and heteropolysaccharide glycopeptide, a mixed lesion of proliferative glomerulonephritis (PGN) with immunofluorescent mesangial pattern and membranous glomerulonephritis (MG) with immunofluorescent granular pattern resulted. It was concluded that PGN was caused by the presence of nephritogenoside and MG by the presence of the heteropolysaccharide glycopeptide in the crude nephritogenic glycopeptide mixtures derived from various solubilization steps used to treat the kidney extracts. Trichloroacetic acid treatment of crude nephritogenic glycopeptide mixtures precipitated the heteropolysaccharide glycopeptide of the MG-inducing factor, thus permitting the separation of nephritogenoside from the heteropolysaccharide glycopeptide by a rather simple technique. Both the heteropolysaccharide glycopeptide and Heymann’s antigen (so-called tubular antigen) have a common antigenic substance, but we cannot conclude, at the present state, that both substances are chemically the same. The degree of contamination of pure nephritogenoside by this substance that is antigenically the same as Heymann’s antigen (in pure nephritogenoside) can be chemically and accurately determined, based on the evidence that pure nephritogenoside is a glycopeptide having only three glucose residues as the sugar moiety, that is, by estimating the amount of contaminated monosaccharide components such as galactose, mannose, and N-acetylglucosamine.

          Related collections

          Author and article information

          S. Karger AG
          04 December 2008
          : 37
          : 2
          : 85-93
          Clinical Research Institute, National Medical Center, Tokyo, Japan
          183220 Nephron 1984;37:85–93
          © 1984 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Original Paper


          Comment on this article